To keep you up-to-date on the latest scientific findings and on the clinical management of CML the iCMLf is pleased to present to you monthly updates from key CML publications in peer-reviewed journals.

The iCMLf 'Publications of the month' are brought to you by Professor Timothy Hughes. From the many papers on CML published this month Professor Hughes has selected topical, interesting papers for your perusal including interesting publications from the emerging regions and recent papers on CML and COVID-19.

Read Professor Hughes' CML publications of the month: August 2021

Clinical papers

• A phase 3, open-label, randomized study of Asciminib, a STAMP inhibitor, vs Bosutininb in CML after ≥ prior TKI’s
  Rea D et al. Blood, August 2021 (epub ahead of print)
• Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial
  Cortes J et al. Blood, August 2021 (epub ahead of print)
• Chronic myeloid leukemia
  Cortes J et al. Lancet, August 2021 (epub ahead of print)
• Inotuzumab ozoganicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
  Jain N et al. Am J Hematol, August 2021
• Pulmonary hypertension in patients with chronic myeloid leukemia
  Song IC et al. Medicine (Baltimore), August 2021 – open access publication
• Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged > 65 years resistant/intolerant to previous tyrosine-kinase inhibitors
  Latagliata R et al. Hematol Oncol, August 2021
• Is the Sokol or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
  Zhang XS et al. Leukemia, August 2021 (epub ahead of print) – open access publication
  
• Tyrosine kinase inhibitor and vascular adverse events in chronic myeloid leukemia patients: a population-based, prospensity score-matched cohort study
  Chen MT et al. Oncologist, August 2021 (epub ahead of print) – open access publication
• Long-term tolerability and efficacy after initial PegIFN- α addition to dasatinib in CML-CP – five year follow-up of the Nord CML007 study
  Flygt H et al. Eur J Haematol, August 2021 (epub ahead of print) – open access publication
  
• Treatment free remission in patients with chronic myeloid leukemia: recommendations of LALNET expert panel
  Pavlovsky C et al. Blood Adv, August 2021 (epub ahead of print) - open access publication
• Treatment-free remission in chronic myeloid leukemia: Can we identify prognostic factors?
  Scifullah HH and Lucas CM. Cancers (Basel), August 2021 – open access publication

Scientific papers

• CRISPR-Cas9 technology as a tool to target gene drivers in cancer: proof of concept and new opportunities to treat chronic myeloid leukemia
  Vuelta E et al. CRISPR J, August 2021
• Genomic copy number variants in CML patients with the Philadelphia chromosome (Ph+): An update
  Zhang H et al. Front Genet, August 2021 – open access publication

Pediatric papers

• Discontinuation of imatinib in children with chronic myeloid leukemia: A study from the International Registry of childhood CML
  Millot F et al. Cancers(Basel), August 2021 – open access publication

ERSAP papers

• Health-related quality of life using EQ-5D among chronic myeloid leukemia patients in health centres in Klang Valley, Malaysia
  Wan Puteh SE et al. PLoS, August 2021 – open access publication

COVID-19 papers

COVID-19 and CML

• The care of the leukemic patients in times of SARS-CoV-2
  Karki NK et al. Curr Oncol Rep, August 2021 – open access publication
• A novel system for semiautomatic sample processing in chronic myeloid leukemia: Increasing throughput without impacting on molecular monitoring at time of SARS-CoV-2 pandemic
  Stella S et al. Diagnostics (Basel), August 2021 – open access publication

COVID-19 and haematological malignancies / cancer

• COVID-19 among patients with haematological malignancies: A national Israeli retrospective analysis with special emphasis on treatment and outcome
  Levy I et al. Leuk Lymphoma, August 2021 (epub ahead of print)
• Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
  Malard F et al. Blood Cancer J, August 2021 – open access publication
• Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
  Greenberger LM et al. Cancer Cell, August 2021 – open access publication